Clinical Trial

Prospective Validation of the Novel PVD-B65 Risk Score in Patients With Chronic Lung Disease and Pulmonary Hypertension

Recruiting
View on ClinicalTrials.gov →
Summary
Prospective observational study to determine if the PVD-B65 risk score for one-year mortality in patients with chronic lung disease and pulmonary hypertension (CLD-PH) can accurately risk stratify these patients and successfully predict one-year mortality from time of pulmonary hypertension diagnosis. PVD-B65 risk score was developed in a retrospective cohort of patients with CLD-PH, utilizing the presence of pulmonary fibrosis without emphysema, pulmonary vascular resistance (PVR) \> 5 woods units (WU), 6-minute walk distance (6MWD) \< 150 meters, B-natriuretic type peptide (BNP) \> 200 pg/mL or N-terminal pro-natriuretic type peptide (NT-proBNP) \> 300 pg/dL, and age \> 65 years as the score components.
Trial Details
NCT Number NCT07151768
Lead Sponsor Temple University
Conditions Chronic Lung Disease, Pulmonary Hypertension
Enrollment 100 participants
Start Date 2025-09-01
Primary Completion 2028-08-31 (estimated)
Study Completion 2028-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-03